The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.

Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ ...

On Wednesday morning, Johnson & Johnson (NYSE:JNJ) published its second-quarter earnings report, but this wasn't greeted ...

Six decades of uninterrupted dividend growth represents a financial commitment that has survived recessions, product liability crises, patent cliffs, and a global pandemic. Johnson & Johnson has ...

Johnson & Johnson is rated Hold, reflecting its defensive profile, strong balance sheet, and fair-to-slight overvaluation per Monte Carlo DCF analysis. JNJ ranks second in peer group quality, with ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Johnson & Johnson has encountered its share of troubles in recent years. Let's briefly go through the list and name some of them. The company is still dealing with thousands of lawsuits from ...

The children of Maria Lozano, who died from mesothelioma in 2024, were plaintiffs in the case against Johnson & Johnson. About two weeks earlier, a jury in Oklahoma County District Court sided with ...

Johnson & Johnson is betting big on America, crediting Trump tax policies, top talent and a strong investment environment for inspiring a $55 billion U.S. investment push that spotlights growing ...

Drug-making giant Johnson & Johnson will officially start marketing four of its medications on the Trump administration's TrumpRx website on Friday, CBS News exclusively learned. The pharmaceutical ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Johnson & Johnson said Monday it will ...